Welcome to the Wyoming Chapter of the American College of Cardiology
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit:
ACC Rockies Chapter Meeting 2025
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- PISCES: Fish Oil Reduces CV Event Risk in Patients on DialysisPatients on maintenance hemodialysis receiving daily fish oil had significantly lower rates of serious cardiovascular events than those receiving placebo, according to the PISCES trial, presented at the American Society of Nephrology Kidney Week Annual Meeting and simultaneously published Nov. 7 in NEJM.
- Eagle’s Eye View: Highlights from the 2025 AHA Scientific SessionsIn this week’s View, Dr. Eagle highlights several important studies presented at the recent American Heart Association Scientific Sessions.
- ACCEL Lite: TACSI Trial: Dual or Single Antiplatelet Therapy After CABG in Patients With ACSIn this interview, Drs. Steven E. Nissen and Anders Jeppsson discuss “TACSI Trial: Dual or Single Antiplatelet Therapy After CABG in Patients With ACSâ€.
- JACC Featured Science: ECG-AI For HF Risk; ANSWER-HF; NEO-MINDSET; MANIFEST-USFeatured science studies simultaneously published in JACC and presented at AHA 2025 looked at artificial intelligence applied to an electrocardiogram (ECG-AI) for heart failure (HF) risk, treatment of Chagas disease, early aspirin withdrawal in STEMI and non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and safety of the pentaspline pulsed-field ablation (PFA) catheter.
- Secondary Cardiovascular Prevention For Survivors of Childhood CancerApproximately half a million people in the United States are survivors of cancer diagnosed in childhood or adolescence. Over 50% of pediatric cancer patients have been treated with curative, but cardiotoxic, anthracycline-based therapies.